Search Results - "Wenham, Robert"

A phase II, multicenter, open-label trial of OTL38 injection for the intra-operative imaging of folate receptor-alpha positive ovarian cancer by Randall, Leslie M., Wenham, Robert M., Low, Philip S., Dowdy, Sean C., Tanyi, Janos L.

“…OTL38 is a folate-indole-cyanine green-like conjugate to folate receptor alpha (FRa). The objectives of this prospective trial were to assess the safety and…”
Get full text

IgA transcytosis and antigen recognition govern ovarian cancer immunity by Biswas, Subir, Mandal, Gunjan, Payne, Kyle K., Anadon, Carmen M., Gatenbee, Chandler D., Chaurio, Ricardo A., Costich, Tara Lee, Moran, Carlos, Harro, Carly M., Rigolizzo, Kristen E., Mine, Jessica A., Trillo-Tinoco, Jimena, Sasamoto, Naoko, Terry, Kathryn L., Marchion, Douglas, Buras, Andrea, Wenham, Robert M., Yu, Xiaoqing, Townsend, Mary K., Tworoger, Shelley S., Rodriguez, Paulo C., Anderson, Alexander R., Conejo-Garcia, Jose R.

“…Most ovarian cancers are infiltrated by prognostically relevant activated T cells 1 – 3 , yet exhibit low response rates to immune checkpoint inhibitors 4 …”
Get full text

Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial by Del Campo, Josep M, Matulonis, Ursula A, Malander, Susanne, Provencher, Diane, Mahner, Sven, Follana, Philippe, Waters, Justin, Berek, Jonathan S, Woie, Kathrine, Oza, Amit M, Canzler, Ulrich, Gil-Martin, Marta, Lesoin, Anne, Monk, Bradley J, Lund, Bente, Gilbert, Lucy, Wenham, Robert M, Benigno, Benedict, Arora, Sujata, Hazard, Sebastien J, Mirza, Mansoor R

“…In the ENGOT-OV16/NOVA trial (ClinicalTrials.gov identifier: NCT01847274), maintenance therapy with niraparib, a poly(ADP-ribose) polymerase inhibitor,…”
Get full text

The molecular biology of endometrial cancers and the implications for pathogenesis, classification, and targeted therapies by Bansal, Nisha, Yendluri, Vimala, Wenham, Robert M

“…Understanding and identifying molecular biology and genetics of endometrial cancer are central to the development of novel therapies. This article reviews the…”
Get more information

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53 -mutant Ovarian Cancer by Oza, Amit M, Estevez-Diz, Maria, Grischke, Eva-Maria, Hall, Marcia, Marmé, Frederik, Provencher, Diane, Uyar, Denise, Weberpals, Johanne I, Wenham, Robert M, Laing, Naomi, Tracy, Michael, Freshwater, Tomoko, Lee, Mark A, Liu, Ji, Qiu, Jingjun, Rose, Shelonitda, Rubin, Eric H, Moore, Kathleen

“…Preclinical studies show that adavosertib, a WEE1 kinase inhibitor, sensitizes -mutant cells to chemotherapy. We hypothesized that adavosertib, plus…”
Get full text

MicroRNA Expression Profiling in Human Ovarian Cancer : miR-214 Induces Cell Survival and Cisplatin Resistance by Targeting PTEN by HUA YANG, KONG, William, CHENG, Jin Q, LILI HE, ZHAO, Jian-Jun, O'DONNELL, Joshua D, JIAWANG WANG, WENHAM, Robert M, COPPOLA, Domenico, KRUK, Patricia A, NICOSIA, Santo V

“…MicroRNAs (miRNA) represent a novel class of genes that function as negative regulators of gene expression. Recently, miRNAs have been implicated in several…”
Get full text

Symptoms of Women With High-Risk Early-Stage Ovarian Cancer by Chan, John K., Tian, Chunqiao, Kesterson, Joshua P., Monk, Bradley J., Kapp, Daniel S., Davidson, Brittany, Robertson, Sharon, Copeland, Larry J., Walker, Joan L., Wenham, Robert M., Casablanca, Yovanni, Spirtos, Nick M., Tewari, Krishnansu S., Bell, Jeffrey G.

“…To assess the presentation, characteristics, and prognostic significance of symptoms in patients with high-risk early-stage epithelial ovarian cancer. A…”
Get full text

A Phase III Study of Pafolacianine Injection (OTL38) for Intraoperative Imaging of Folate Receptor-Positive Ovarian Cancer (Study 006) by Tanyi, Janos L, Randall, Leslie M, Chambers, Setsuko K, Butler, Kristina A, Winer, Ira S, Langstraat, Carrie L, Han, Ernest S, Vahrmeijer, Alexander L, Chon, Hye Sook, Morgan, Mark A, Powell, Matthew A, Tseng, Jill H, Lopez, Alexis S, Wenham, Robert M

“…The adjunctive use of intraoperative molecular imaging (IMI) is gaining acceptance as a potential means to improve outcomes for surgical resection of…”
Get full text

Prevalence of viral DNA in high-grade serous epithelial ovarian cancer and correlation with clinical outcomes by Robertson, Sharon E, Yasukawa, Maya, Marchion, Douglas C, Xiong, Yin, Naqvi, Syeda Mahrukh Hussnain, Gheit, Tarik, Tommasino, Massimo, Wenham, Robert M, Giuliano, Anna R, Lancaster, Johnathan M, Shahzad, Mian M K

“…Currently 11 infectious agents are classified as carcinogenic but the role of infectious agents on outcomes of epithelial ovarian cancer is largely unknown. To…”
Get full text

Prognostic features of endometrial cancer metastasis to the central nervous system by Kuznicki, Michelle L, Mallen, Adrianne, Ha, Kristal, McClung, Emily Clair, Castaneda, Antonio V, Cao, Biwei, Fridley, Brooke L, Chon, Hye Sook, Chern, Jing Yi, Hoffman, Mitchel, Wenham, Robert M, Matsuo, Koji, Shahzad, Mian M. K

“…Objectives Central nervous system metastases (CNSm) secondary to endometrial cancer (EC) are rare. As a result, prognostic factors for this patient population…”
Get full text

Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells by Anadon, Carmen M., Yu, Xiaoqing, Hänggi, Kay, Biswas, Subir, Chaurio, Ricardo A., Martin, Alexandra, Payne, Kyle K., Mandal, Gunjan, Innamarato, Patrick, Harro, Carly M., Mine, Jessica A., Sprenger, Kimberly B., Cortina, Carla, Powers, John J., Costich, Tara Lee, Perez, Bradford A., Gatenbee, Chandler D., Prabhakaran, Sandhya, Marchion, Douglas, Heemskerk, Mirjam H.M., Curiel, Tyler J., Anderson, Alexander R., Wenham, Robert M., Rodriguez, Paulo C., Conejo-Garcia, Jose R.

“…Despite repeated associations between T cell infiltration and outcome, human ovarian cancer remains poorly responsive to immunotherapy. We report that the…”
Get full text

The role of menopausal hormone therapy in women with or at risk of ovarian and breast cancers: Misconceptions and current directions by Temkin, Sarah M., Mallen, Adrianne, Bellavance, Emily, Rubinsak, Lisa, Wenham, Robert M.

“…For women who are candidates for menopausal hormone therapy (MHT), estrogen can provide relief from symptomatic menopause, decrease rates of chronic illnesses,…”
Get full text

Impact of age, comorbidity, and treatment characteristics on survival in older women with advanced high grade epithelial ovarian cancer by Mallen, Adrianne, Todd, Sarah, Robertson, Sharon E., Kim, Jongphil, Sehovic, Marina, Wenham, Robert M., Extermann, Martine, Chon, Hye Sook

“…Older women have a worse prognosis with advanced epithelial ovarian cancer (EOC) and comorbidities likely contribute to poor outcomes. We sought to identify…”
Get full text

Utilizing digital pathology to quantify stromal caveolin-1 expression in malignant and benign ovarian tumors: Associations with clinicopathological parameters and clinical outcomes by Saeed-Vafa, Daryoush, Marchion, Douglas C, McCarthy, Susan M, Hakam, Ardeshir, Lopez, Alexis, Wenham, Robert M, Apte, Sachin M, Chen, Dung-Tsa, Magliocco, Anthony M, Lancaster, Johnathan M, Reid, Brett M, Permuth, Jennifer B

“…Loss of stromal caveolin-1 (Cav-1) is a biomarker of a cancer-associated fibroblast (CAF) phenotype and is related to progression, metastasis, and poor…”
Get full text

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial by Sandhu, Shahneen K, MD, Schelman, William R, MD, Wilding, George, MD, Moreno, Victor, MD, Baird, Richard D, PhD, Miranda, Susana, BSc, Hylands, Lucy, BSc, Riisnaes, Ruth, FIBMS, Forster, Martin, PhD, Omlin, Aurelius, MD, Kreischer, Nathan, MSc, Thway, Khin, MD, Gevensleben, Heidrun, MD, Sun, Linda, PhD, Loughney, John, PhD, Chatterjee, Manash, PhD, Toniatti, Carlo, PhD, Carpenter, Christopher L, MD, Iannone, Robert, MD, Kaye, Stan B, Prof, de Bono, Johann S, Prof, Wenham, Robert M

“…Summary Background Poly(ADP-ribose) polymerase (PARP) is implicated in DNA repair and transcription regulation. Niraparib (MK4827) is an oral potent, selective…”
Get full text

Phase Ib Study of Navicixizumab Plus Paclitaxel in Patients With Platinum-Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancer by Fu, Siqing, Corr, Bradley R, Culm-Merdek, Kerry, Mockbee, Colleen, Youssoufian, Hagop, Stagg, Robert, Naumann, R Wendel, Wenham, Robert M, Rosengarten, Rafael D, Benjamin, Laura, Hamilton, Erika Paige, Moore, Kathleen N

“…This phase Ib study evaluated the safety and efficacy of paclitaxel plus navicixizumab, a bispecific antiangiogenic antibody to vascular endothelial growth…”
Get full text

Twenty-year surgical trends in a gynecologic oncology fellowship training program: Implications for practice by Hoffman, Mitchel S., Xiong, Yin, Apte, Sachin, Roberts, William, Wenham, Robert M.

“…To assess whether there were any significant changes in surgical training volume over the past 20 years that might have ramifications toward preparedness for…”
Get full text

Surgical prevention strategies in ovarian cancer by Mallen, Adrianne, Soong, T. Rinda, Townsend, Mary K., Wenham, Robert M., Crum, Christopher P., Tworoger, Shelley S.

“…Given the current lack of effective screening for ovarian cancer, surgical removal of at-risk tissue is the most successful strategy to decrease risk of cancer…”
Get full text

Phase II Study of Bevacizumab in Patients With Platinum-Resistant Ovarian Cancer or Peritoneal Serous Cancer by CANNISTRA, Stephen A, MATULONIS, Ursula A, MCGUIRE, William, PENSON, Richard T, HAMBLETON, Julie, DUPONT, Jakob, MACKEY, Howard, DOUGLAS, Jeffrey, BURGER, Robert A, ARMSTRONG, Deborah, WENHAM, Robert

“…We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous carcinoma (PSC)…”
Get full text

A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer by Vergote, Ignace, Heitz, Florian, Buderath, Paul, Powell, Matthew, Sehouli, Jalid, Lee, Christine M., Hamilton, Anne, Fiorica, James, Moore, Kathleen N., Teneriello, Michael, Golden, Lisa, Zhang, Wei, Pitou, Celine, Bell, Robert, Campbell, Robert, Farrington, Daphne L., Bell-McGuinn, Katherine, Wenham, Robert M.

“…This phase 1b/2 clinical trial (NCT01663857) evaluated the efficacy of ralimetinib in combination with gemcitabine (G) and carboplatin (C), followed by…”
Get full text